Search results
7 paź 2023 · The PATHFINDER study provides early evidence of the feasibility of blood testing to screen for multiple cancers with a single test, a departure from the prevailing framework requiring distinct screening tests for each cancer type.
OneTest™ is one of the most affordable tools to help detect cancers early. Recent studies have demonstrated that genetics only accounts for around 5% of cancers. Those concerned about their risk of cancer, even with little or no family history, may benefit from routine cancer marker testing.
A new type of liquid biopsy test can predict the recurrence of breast cancer in high-risk patients, months or even years before they relapse, research by a team from The Institute of Cancer Research, London, has shown.
11 wrz 2022 · New tests can detect common cancer signal across over 50 types of cancer from tumour DNA in blood; Latest results are an important first step to early detection of previously hard to find cancers; Cancer services must step up to redefine early cancer detection and the provision of care
21 lip 2020 · In this study, the authors develop a non invasive blood test based on circulating tumor DNA methylation that can potentially detect cancer occurrence even in asymptomatic patients.
25 sie 2023 · Multi-cancer early detection (MCED) tests have captured the attention of doctors, researchers and patients due to their potential to detect a range of cancers through a simple blood test. But are these tests reliable?
A validated blood-based multi-cancer early detection (MCED) test uses cfDNA and machine learning to detect a common cancer signal across >50 cancer types and predict cancer signal origin (CSO). PATHFINDER is a prospective study in a screening population that evaluated the clinical feasibility of MCED testing.
